Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1

Inclusion Criteria: * Healthy male and female volunteers, 18-60 years of age; no clinically significant findings reported following detailed physical examination, medical history, vital signs, clinical laboratory tests, and ECGs as deemed by the PI * Body mass index (BMI) in the range of 18 to 32 kg/m2 (inclusive) and weighing at least 50 kg * Non-smokers / non-users of nicotine containing products for at least the previous 3 months * Agreement to use birth control during the study and 3 months post last visit * Able to comply with all protocol requirements and procedures Exclusion Criteria: * Clinically significant abnormalities found during physical examination, medical history review, ECGs (including QTcf interval \> 450 msec), vital signs and laboratory tests (including positive test for HIV, hepatitis B and/or C) * History of any serious allergic reaction to any medication * Participated in a previous clinical trial with an investigational product in the last 60 days * Any blood or plasma donation or other loss of blood at a volume exceeding 500 mL within 3 months before dosing * History of drug or alcohol abuse in the last 2 years and positive test for drug abuse * Use of any systemic medication within the past 2 weeks, including use of herbal products * Pregnant or lactating women * Any other issue which, in the opinion of the PI, will make the subject ineligible for study participation